When to Call the Doctor During Prostate Cancer Treatment – Learning about Infections and Deep Vein Thrombosis

Having prostate cancer and prostate cancer treatments may cause side effects that require the immediate attention of your doctor or health care team, but it is hard to know when to call the doctor as opposed to knowing when to let it ride. Infection It can even be difficult to know when all you have [...]

Prostate Cancer with a Gleason 7 – Different Outcomes Between Gleason 4 + 3 and Gleason 3 + 4 – Changing Treatment Directions

A Gleason Score of 7 is often looked at as a middle range score, but clearly not as serious as an 8 or 9 score. Some recently combined research performed at the Department of Urology, University of Washington School of Public Health, Seattle, Washington and the Division of Public Health Sciences, Fred Hutchinson Cancer Research [...]

Medicines to Deter Some Cancers Are Not Taken, Comments about A NYT Article

GINA KOLATA, in her continuing series in the New York Times, on the war against cancer, published in today’s edition another story that has great relevance for us advanced prostate cancer survivors. The story is about American’s failure to take certain drugs that have been demonstrated to prevent cancer while Americans are very happy to [...]

By |2017-10-19T10:54:15-04:00November 13th, 2009|Uncategorized|0 Comments

Stereotactic Radio Surgery (SRS) Successfully Treats Pain in Patients with Advanced Cancer that has Spread to Bones

According to researchers from University of Pittsburgh Cancer Institute (UPCI), Stereotactic Radio Surgery (SRS), which was developed at UPCI, can successfully control pain in patients with cancer that has spread to the spine. SRS is a procedure that precisely delivers a large dose of radiation directly to tumors. The researchers from UPCI, led by Dwight [...]

On the Horizon – A Quick Summary of the Status of Some of the Up Coming Treatments for Advanced Prostate Cancer

Provenge, a cancer vaccine, has demonstrated its ability to improve the survival of men with castrate resistant prostate cancer (CRPC). The developer, Dendreon, has submitted it latest clinical trial data to the FDA for approval. We hope to have an approval by mid-year 2010. Growth factors were thought to be potential targets for treating prostate [...]

Go to Top